Published in Subst Abuse Treat Prev Policy on July 09, 2013
A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada. Subst Abuse Treat Prev Policy (2014) 0.81
A cost-benefit/cost-effectiveness analysis of an unsanctioned supervised smoking facility in the Downtown Eastside of Vancouver, Canada. Harm Reduct J (2014) 0.80
Cost-Effectiveness of Combined Sexual and Injection Risk Reduction Interventions among Female Sex Workers Who Inject Drugs in Two Very Distinct Mexican Border Cities. PLoS One (2016) 0.77
Examining the potential role of a supervised injection facility in Saskatoon, Saskatchewan, to avert HIV among people who inject drugs. Int J Health Policy Manag (2015) 0.75
Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study. Harm Reduct J (2017) 0.75
Use of on-site detoxification services co-located with a supervised injection facility. J Subst Abuse Treat (2017) 0.75
Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85
Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis (2006) 3.72
Needle exchange programs: an economic evaluation of a local experience. CMAJ (1997) 2.46
A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. Int J Drug Policy (2009) 2.04
Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 2.00
Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ (2013) 1.95
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology (2011) 1.67
Is Vancouver Canada's supervised injection facility cost-saving? Addiction (2010) 1.65
The cost-effectiveness of Vancouver's supervised injection facility. CMAJ (2008) 1.39
Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.37
Estimating the size of hard-to-reach populations: a novel method using HIV testing data compared to other methods. AIDS (2001) 1.23
Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol (2010) 1.07
Association between neighbourhood socioeconomic characteristics and high-risk injection behaviour amongst injection drug users living in inner and other city areas in Montréal, Canada. Int J Drug Policy (2009) 1.04
Cost-effectiveness of syringe exchange as an HIV prevention strategy. J Acquir Immune Defic Syndr (2001) 1.04
Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention. Int J Drug Policy (2006) 1.01
HIV and HCV discordant injecting partners and their association to drug equipment sharing. Scand J Infect Dis (2009) 0.98
How many HIV infections are prevented by Vancouver Canada's supervised injection facility? Int J Drug Policy (2011) 0.96
Potential role of safer injection facilities in reducing HIV and hepatitis C infections and overdose mortality in the United States. Drug Alcohol Depend (2011) 0.95
Associations between HIV-related injection behaviour and distance to and patterns of utilisation of syringe-supply programmes. J Epidemiol Community Health (2008) 0.95
Cost effectiveness of Streetworks' needle exchange program of Edmonton. Can J Public Health (1999) 0.90
Study size and documentation to detect injection-related hepatitis C in prison. QJM (1998) 0.89
Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026. Int J Drug Policy (2010) 0.87
Science versus politics: the need for supervised injection facilities in Montreal, Canada. Int J Drug Policy (2012) 0.85
Evaluating Vancouver's supervised injection facility: data and dollars, symbols and ethics. CMAJ (2008) 0.84
Drug use patterns in the presence of crack in downtown Montréal. Drug Alcohol Rev (2011) 0.82
Obesity relationships with community design, physical activity, and time spent in cars. Am J Prev Med (2004) 7.83
A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada. Subst Abuse Treat Prev Policy (2014) 0.81
Suicide and unemployment: a panel analysis of Canadian provinces. Arch Suicide Res (2014) 0.75